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Abstract
To evaluate the mechanism of the development of therapeutic resistance after temozolomide treatment, we
focused on changes in O6-methylguanine DNA methyltransferase (MGMT) and mismatch repair (MMR) between
initial and recurrent glioblastomas. Tissue samples obtained from 24 paired histologically confirmed initial and re-
current adult glioblastoma patients who were initially treated with temozolomide were used for MGMT and MMR
gene promoter methylation status and protein expression analysis using methylation-specific multiplex ligation
probe amplification (MS-MLPA), methylation-specific polymerase chain reaction (MSP), and immunohistochemical
staining. There was a significant decrease in the methylation ratio of the MGMT promoter determined by
MS-MLPA, which was not detectable with MSP, andMGMT protein expression changes were not remarkable.
However, there was no epigenetic variability in MMR genes, and a relatively homogeneous expression of MMR
proteins was observed in initial and recurrent tumors. We conclude that the development of reduced methylation
in theMGMT promoter is one of the mechanisms for acquiring therapeutic resistance after temozolomide treatment
in glioblastomas.
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Introduction
Glioblastoma still remains a devastating brain cancer with an unsatis-
factory survival rate of 12 to 15 months despite recent advances in the
best standard therapies, which include surgical resection, radiation,
and temozolomide [1]. The majority of glioblastomas eventually
progress or relapse, regardless of whether the O6-methylguanine
DNA methyltransferase (MGMT ) promoter in the tumor tissue is
methylated [1,2]. The role of MGMT promoter methylation in glio-
blastoma as a prognostic biomarker is well established, and the status
of MGMT is considered as a major determinant for temozolomide
sensitivity [3]. MGMT removes methyl and chloroethyl groups from
the O6 position of guanine produced by the alkylating agent, and
overexpression of MGMT can rescue cancer cells from anticancer
drugs [4]. However, MGMT activity, indirectly analyzed by MGMT
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promoter methylation using methylation-specific polymerase chain
reaction (MSP) in initial tumor tissue, could not be used to predict
the response to the recurrent tumor treated with temozolomide [5].
Additional important determinants related to temozolomide
sensitivity are the DNA mismatch repair (MMR) genes. MMR func-
tions in resistance to the alkylating agent; when O6-methylguanine
is not repaired by MGMT before DNA replication, there is a re-
sulting DNA gap, which if not corrected permanently leads to
DNA double-strand breaks and apoptotic cell death [6]. Therefore,
intact MMR is required for the death of cancer cells treated with an
alkylating agent, such as temozolomide, in an MGMT-deficient
condition. Previous reports indicated that there are low occurrences
of MMR defects and consistent expression of MMR proteins in
newly diagnosed adult glioblastoma samples [7–10]. However,
studies evaluating MMR status in recurrent glioblastomas in re-
lation to therapeutic resistance are sparse or reveal controversial
results [11,12].
Therefore, the development of therapeutic resistance to temozolo-
mide may harbor genetic changes or clone selections for resistant
cells, including alterations inMGMT and/orMMR genes. To address
this issue, we investigated alterations in the promoter methylation
status and protein expression of MGMT and MMR genes in paired
initial and recurrent glioblastoma tissues. All of the patients were ini-
tially treated with temozolomide. In the present study, we used the
semiquantitative method of methylation-specific multiplex ligation
probe amplification (MS-MLPA) for a closer evaluation of changes
in the promoter methylation status of MGMT and MMR genes,
and the results were compared with those of the standard method
of MSP and protein expression levels evaluated by immunohisto-
chemical (IHC) staining.
Materials and Methods
Study Population and Preparation of Tissue Samples
Clinical data and tissue samples were obtained from 24 paired
histologically confirmed initial and recurrent adult glioblastoma
patients who had undergone initial treatment of surgical resection,
followed by a temozolomide-based regimen and reoperation at recur-
rence. The initial treatment protocol includes the following: standard
concomitant radiation therapy and temozolomide followed by adju-
vant temozolomide in 14 patients, neoadjuvant chemotherapy with
nimustine and cisplatin followed by radiation therapy and adjuvant
temozolomide in 6 patients, radiation therapy followed by adjuvant
temozolomide in 3 patients, and temozolomide only in 1 patient. The
mean age was 60.1 years (range, 30–73), and 15 patients (62.5%)
were male. A median total dose of administered temozolomide before
recurrence was 7800 mg (range, 1200–20,150), and the median pe-
riod of relapse after initial surgery was 8 months (range, 2–55). Insti-
tutional review board approval was obtained for the data collection
and study analysis.
Snap-frozen tumor tissues obtained during surgery and kept in
liquid nitrogen at −80°C were used for MS-MLPA. DNA was iso-
lated from the tissue samples using the QIAGEN DNA Mini Kit
(QIAGEN Inc., Valencia, CA) according to the manufacturer’s pro-
tocol. CpGenome Universal Methylated DNA and Unmethylated
DNA (Chemicon, Millipore, Billerica, MA) were included as controls
in each set of MS-MLPA and MSP experiments. Paraffin-embedded
tissues were subjected to MSP and IHC staining.
Methylation-specific Multiplex Ligation Probe Amplification
The methylation status of the MGMT promoter and MMR genes
were analyzed using the MS-MLPA probe mix prepared by MRC-
Holland (Salsa MS-MLPA Kit ME011 MMR version B1, Amsterdam,
The Netherlands), which includes six probes for MLH1, four probes
for MSH2, three probes for MSH6, three probes for PMS2, and six
probes specific for the MGMT promoter region. The detailed pro-
cedure is described in previous publications [13,14]. A methylation-
sensitive restriction enzyme, HhaI (R6441; Promega, Madison, WI),
which cuts unmethylated GCGC sites, was applied to each set of
samples. The resultant polymerase chain reaction fragments were
separated by capillary gel electrophoresis (ABI Prism 7000/7700;
Applied Biosystems, Foster City, CA). The methylation status was
quantified using GeneMarker software (version 1.5; Soft Genetics,
State College, PA). To evaluate the methylation status, the “meth-
ylation ratio” was calculated by dividing each normalized peak value
of the HhaI enzyme–digested sample by that of the corresponding
undigested sample. This value corresponds to the percentage of
methylated sequences.
Methylation-specific Polymerase Chain Reaction
The methylation status of the MGMT promoter was also analyzed
using MSP, and the results were compared with those of MS-MLPA.
Prepared DNA was modified by sodium bisulfite treatment using
an EZ DNA Methylation-Gold Kit (Catalogue No. D5005; Zymo
Research, Orange, CA). The primer sequences used for the MGMT
were given as follows: methylated forward, 5′ TTT CGA CGT TCG
TAG GTT TTC GC 3′; methylated reverse, 5′ GCA CTC TTC
CGA AAA CGA AAC G 3′; unmethylated forward, 5′ TTT GTG
TTT TGA TGTTTG TAGGTT TTTGT 3′; unmethylated reverse,
5′ AAC TCC ACA CTC TTC CAA AAA CAA AAC A 3′. The
annealing temperature was 64°C. The obtained polymerase chain
reaction products were electrophoresed in 2% agarose gels and vi-
sualized under UV illumination after staining with ethidium bro-
mide. The evaluation of the assay results was performed as described
previously [13].
IHC Staining
Tissue expression of MMR proteins (PMS2, MLH1, MSH2, and
MSH6) and MGMT protein were confirmed by IHC staining using
conventional methods according to the manufacturer’s protocols. The
antibodies used were given as follows: MGMT (MS-470-P, 1:100;
Neomarkers, Fremont, CA), PMS2 (1:50; Cell Marque, Rocklin,
CA), MLH1 (1:50; DAKO, Glostrup, Denmark), MSH2 (1:200;
Invitrogen, Camarillo, CA), and MSH6 (1:50, Cell Marque). IHC
staining results were semiquantitatively graded as follows: no staining
detected (0; no positive tumor cells), faint staining (1+; <10% positive
tumor cells), moderate staining (2+; 10–50% positive tumor cells),
and strong staining (3+; >50% positive tumor cells). Positive staining
was defined as 2+ or 3+ nuclear staining based on the percentage of
tumor cells showing immunoreactivity.
Statistical Analysis
The Wilcoxon signed rank test and McNemar test were used for
nonparametric comparisons between the results of initial and recur-
rent samples. Statistical significance was accepted at probability val-
ues of less than 0.05. These statistical analyses were performed with
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the aid of IBM SPSS Statistics software (version 19.0; SPSS Inc.,
Chicago, IL).
Results
Changes in MGMT
A total of 24 paired cases of initial and recurrent glioblastoma sam-
ples were analyzed with MSP for MGMT promoter methylation sta-
tus and IHC staining for MGMT protein expression, and the results
are summarized in Table 1. TheMGMT promoter was methylated in
8 (33%) patients and was unmethylated in 16 (67%) patients with
initial glioblastoma. At recurrence, 22 of 24 patients (92%) showed
identical results of MGMT promoter methylation levels measured by
MSP, and their changes were statistically nonsignificant (P = 1.00).
One patient exhibited a reversal of MGMT promoter status from
methylated to unmethylated, and the opposite occurred in another
patient. The MGMT protein was not expressed in 15 (63%) patients
and was expressed in 9 (37%) patients with initial glioblastoma.
Among all of the patients, 19 of 24 patients (79%) showed no changes
in MGMT protein expression at tumor recurrence. Using the cutoff
value of 10% positivity in tumor cells, four (17%) patients showed a
new expression of MGMT protein, and the expression was lost in one
(4%) patient at tumor recurrence. However, their changes were also
statistically nonsignificant (P = .38).
Among the study population, fresh frozen samples were available
for a total of 12 paired cases, and MS-MLPA was performed with
their 24 samples. Figure 1 shows the MGMT promoter methylation
status expressed as the methylation ratio after MS-MLPA analysis of
12 paired initial and recurrent glioblastomas. There was a decrease
in the methylation ratio of the MGMT promoter in recurrent tumor
tissue observed in 9 of 12 cases (75%). Of the other three cases, all
of which had methylation ratios of 0 at initial tumor, two cases
showed an increase in the methylation ratio to 0.1, and one case
showed no change. There was a significant decrease of the methyla-
tion ratio (P = .04, Figure 2) of the MGMT promoter between ini-
tial (median methylation ratio of 0.15) and recurrent glioblastomas
(median methylation ratio of 0.08). These decreases in MGMT pro-
moter methylation were undetectable using the MSP method in all
12 paired cases. Additionally, nonsignificant relationships were observed
between MGMT protein expression and MGMT promoter methyla-
tion changes (P = .07), and the decreased methylation ratio was not
significantly related to the temozolomide administered (P = 1.00).
Changes in MMR
The results of IHC staining for MMR proteins (PMS2, MLH1,
MSH2, and MSH6) in all 24 paired cases showed expression of MMR
proteins at initial tumor, and their expression was preserved at recurrent
tumor in most of the cases. Although the changes of immunoreactivity
Figure 1. Changes in the methylation ratio of the MGMT promoter between initial and recurrent glioblastomas in 12 paired cases mea-
sured by MS-MLPA. The MSP results of the methylation status of the MGMT promoter are indicated by the bar colors, and MGMT
protein expression is indicated by an asterisk.
Table 1. Summary of MGMT Promoter Methylation Status (by MSP) and Protein Expression (by IHC Staining) in a Total of 24 Paired Cases of Initial and Recurrent Glioblastomas.
Recurrent Glioblastoma Identical with Initial Tumor P Value (McNemar Test)
Initial glioblastoma, n (%) MSP Methylated Unmethylated
Methylated 7 (29%) 1 (4%) 22 (92%) 1.00
Unmethylated 1 (4%) 15 (63%)
IHC staining No expression Expression
No expression 11 (46%) 4 (17%) 19 (79%) .38
Expression 1 (4%) 8 (33%)
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at recurrence were relatively obvious in MSH2 (42%) and MSH6
(29%) compared with those in PMS2 (16%) and MLH1 (16%), none
of the proteins reached significant levels (Figure W1 and Table W1).
The MS-MLPA for MMR gene (PMS2, MLH1, MSH2, and MSH6)
promoters demonstrated that all of 12 paired cases analyzed showed a
methylation ratio of 0 in initial and recurrent tumors without exception.
Discussion
To maintain the effective anticancer effect of temozolomide, inactiva-
tion of theMGMT gene and intact expression ofMMR genes in tumor
cells are the key conditions in glioblastomas. There have been studies
that attempt to explain the mechanism of therapeutic resistance in
glioblastoma by evaluating MGMT and MMR gene status changes
in initial and recurrent tumors [12,15–18]. However, inconsistent
results have rendered answers for this issue that remain controversial.
After varied treatment failures in serial samples in glioblastoma,
several studies have advocated for alterations in MGMT promoter
methylation. Parkinson et al. observed changes in MGMT promoter
methylation in 2 of 9 cases (all from unmethylated to methylated)
analyzed by MSP and in 7 of 10 cases (increased methylation in 5
cases and decreased methylation in 2 cases) assessed by sequencing of
25 CpG dinucleotides in the MGMT promoter [15]. They also ob-
served minimal changes in MGMT IHC staining [15]. Jung et al.
reported changes in MGMT promoter methylation in 4 of 16 cases
(from methylated to unmethylated in 3 cases and vice versa in 1 case)
in the second operation samples of recurrent glioblastoma assessed
by MSP [16]. They also showed that 15 of 18 specimens exhibited
higher levels of MGMT protein expression compared to previous sam-
ples by IHC staining [16]. Brandes et al. observed that significant
changes in the MGMT promoter methylation status during the course
of glioblastoma occur more frequently in methylated (to unmethylated
at recurrence in 8 of 13 cases, 61.5%) than unmethylated cases (to
methylated at recurrence in 6 of 25 cases, 24%) assessed by MSP
[17]. The concordance of MGMT promoter methylation assessed by
MSP between initial and recurrent glioblastomas was 63% in their
study [17].
Although the above-mentioned reports shared the result of altera-
tions in MGMT promoter methylation at recurrence detected by the
qualitative method of MSP, the frequency of alteration detection is
relatively uncommon. In the present study, we also found only two
cases (8%) of altered MGMT promoter methylation determined by
MSP. However, when we employed the semiquantitative method of
MS-MLPA, the majority of case pairs revealed alterations in methyl-
ation with the tendency of a decreased methylation ratio in spite of
no changes detected by MSP. Therefore, progressive unmethylation
of the MGMT promoter, presumably in association with increased
expression of MGMT is a plausible mechanism for acquiring thera-
peutic resistance in glioblastoma after temozolomide treatment. The
result of IHC staining for MGMT protein was not helpful for ver-
ifying this hypothesis. However, the value of semiquantitative MS-
MLPA analysis of MGMT promoter methylation was documented
for the management of glioblastoma in previous studies [13,14,19].
Christmann et al. reported evidence supporting the results of the
present study [18]. They showed significant up-regulation of MGMT
enzyme activity in recurrent glioblastoma compared with initial tu-
mor, and the difference was more evident in the temozolomide treat-
ment group compared with the radiation therapy–only group [18].
Additionally, the correlation of MGMT enzyme activity and MGMT
promoter methylation determined by MSP was reasonable only if the
samples with a hemimethylated MGMT promoter were excluded [18].
Moreover, only a moderate correlation between MGMT enzyme activ-
ity and MGMT immunoreactivity was observed, indicating that IHC
staining is only an approximate method for detecting the expression
level of MGMT in glioblastomas [18].
In the present study, we could not find any evidence ofMMR genes
being involved in a possible mechanism for therapeutic resistance.
Major MMR genes, such as PMS2, MLH1, MSH2, and MSH6, were
invariably expressed in initial glioblastoma, and most of the genes were
expressed in the recurrent tumor. However, there is a study showing a
contradictory result to ours [12]. Among the other sporadic reports
regardingMMR genes and therapeutic response or resistance in glioma,
several studies mentioned the development of an inactivating mutation
in MSH6 during the temozolomide treatment, which mediates thera-
peutic resistance in glioblastoma [20–22]. However, Maxwell et al.
demonstrated contradictory results showing no role for MMR defi-
ciency, including MSH6 expression, for mediating temozolomide resis-
tance in malignant glioma [11]. As the loss of MMR usually results in
increase in insertion/deletion mutations particularly in repetitive se-
quence microsatellite DNA, microsatellite instability is a recognized
surrogate biomarker for the loss of MMR function [23]. Low frequency
of microsatellite instabilities found in relapsed glioma samples in pre-
viously reported study also implies the limited role of MMR system
in mediating treatment resistance [7]. However, still there is a possibil-
ity that MMR genes, especially MSH2 and MSH6, have some role for
temozolomide resistance in a small subset of patients, allowing for
our data showing decreased expression of MSH2 by 26% and that of
MSH6 by 21% of the study population (Figure W1 and Table W1).
Therefore, further evidence is still required to answer the controversial
issue of the role ofMMR genes in therapeutic resistance in glioblastoma
after temozolomide treatment.
In summary, semiquantitatively measured reduced methylation of
the MGMT promoter in recurrent glioblastoma after temozolomide
treatment is one of the mechanisms for the acquisition of therapeutic
resistance.MMR deficiency is not the major mechanism of temozolomide
resistance in glioblastoma treatment, asMMR genes showed no variability
Figure 2.We observed a significant difference (*P= .04, Wilcoxon
signed rank test) in the distribution of methylation ratios between
initial and recurrent tumors (median methylation ratio: 0.15 vs 0.08)
determined by MS-MLPA.
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in their unmethylated promoter statuses and they exhibited homoge-
neous expression in both initial and recurrent glioblastomas. Whether
this genetic change is the result of clone selections for resistant cells
or de novo modification of existing tumor cells is to be evaluated in
further studies.
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Figure W1. Changes in the immunoreactivity of MMR proteins between initial and recurrent glioblastomas in 24 paired cases measured
by IHC staining. The changes were nonsignificant for all MMR proteins (McNemar test).
Table W1. Summary of MMR Protein Expression (by IHC Staining) in a Total of 24 Paired Cases
of Initial and Recurrent Glioblastomas.
Recurrent Glioblastoma, n (%) Identical with Initial
Tumor, n (%)
0 or 1+ 2+ 3+
Initial glioblastoma, n (%) PMS2
0 or 1+ 1 (4%) 0 1 (4%) 20 (84%)
2+ 0 0 1 (4%)
3+ 0 2 (8%) 19 (80%)
MLH1
0 or 1+ 1 (4%) 0 1 (4%) 20 (84%)
2+ 0 1 (4%) 1 (4%)
3+ 0 2 (8%) 18 (76%)
MSH2
0 or 1+ 0 2 (8%) 1 (4%) 14 (58%)
2+ 0 1 (4%) 1 (4%)
3+ 0 6 (26%) 13 (54%)
MSH6
0 or 1+ 1 (4%) 1 (4%) 0 17 (71%)
2+ 0 2 (8%) 1 (4%)
3+ 2 (8%) 3 (13%) 14 (59%)
